Monday, 24 Feb 2020

Biologic/Novel Rx

Date Typesort ascending Title Save
06 Jun 2016 Social Did you know that many (not all) biologics have latex? Dr. Dao writes how to Handle Latex Allergies w/ Biologics https://t.co/ToK3AmcAoX
08 Jun 2015 Social 967 pts Orencia RA registry (ORA) shows SIE rate 4.1/100PY. Predictive factors: age & # prior SIE or recurrent infx http://t.co/wrucZOW9HC
14 Apr 2017 Social Are there issues with BIOSIMILAR Safety, Switching or Cost? Patient survey: please vote 5 quick questions here https://t.co/ZvCVlif6Ij
20 Oct 2017 Social RT @emartinmola: High ‘nocebo’ effect observed when patients knowingly switch to a biosimilar https://t.co/IenWgRZUQL
14 Sep 2018 Social FDA approves SC Actemra (tocilizumab) for systemic JIA (Still's disease) +/-MTX. IV TCZ was FDA approved In 2011 for SJIA. Approval is based on JIGSAW, a 52-wk study. sJIA dosing based on Weight ( <30 kg-162 mg q2wk; ≥30 162 mg qwk) https://t.co/kWXdwAh35Z
11 Aug 2015 Social Tapering Biologic Tx Likely to Fail When ultrasound detected Synovitis Is Present http://t.co/j3nExzwW99
09 May 2019 Social Biologic Survival study from Japan- ANSWER study w/ 4466 courses in 2494 pts (2009-17). Efficacy Survival best for ABA, TCZ; worst for IFX & CZP. Toxicity Dropouts most in IFX & ADA, least ABA & CZP. Remission best w/ ETN & ABA, least w/ GLM, IFX. https://t.co/IgRDKLemjW
05 May 2017 Social Japan Study shows 8mg IV Actemra can be escalated to q3 wks IV or reduced to q5 wks IV according to q4wk response https://t.co/rLn6aJowry
07 Nov 2017 Social RT @DrPetryna: #16L #acr17 no risk of DVTorPE w/Tofa from RTC trials analysis. IRs comparable to #corona data for Tofa&cDMARDs @RheumNow ht…
23 Nov 2015 Social The new Etanercept biosimilar (SB4) in the EU is named Benepali, EMA recommended for RA, PsA, SpA & plaque psoriasis https://t.co/6tbvbO7cHY
22 Nov 2016 Social RT @DrPetryna: Sarilumab (IL6R) superior to Humira in MONARCH phase 3 trial. neutropenia &abn LFT > with sarilumab https://t.co/2Rwxz8hiZQ…
29 Jan 2017 Social CHMP sends a positive recommendation for tofacitinib to the EMA. This would be for the 5 mg bid dose mod-severe RA https://t.co/OlN3Eyqya4
19 Oct 2015 Social Here's a primer on Biosimilars, interchangibility and current issues under FDA review. https://t.co/UyhCBuQpsI
06 Aug 2019 Social FDA has approved Turalio (pexidartinib) for the treatment of adults with the rare disorder, tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not responsive to improvement with surgery. https://t.co/eMTmFSW97A
24 May 2018 Social Sandoz announces the approval of its infliximab biosimilarZessly (infliximab) by the European Commission. It is approved for use in RA, , adult & pediatric Crohn’s, adult & pediatric ulcerative colitis, AS, PsA and plaque psoriasis https://t.co/V0PJHbeLSp
15 Mar 2016 Social 63 Actemra nonresponders switched to TNFi (41) or Orencia (22) - more TNFi achieved LDAS (CDAI<10) (64% vs 24% ABA) https://t.co/xmAuMJN4Gd
12 Jan 2017 Social Biosimilar Inflectra priced at only a 15% discount; CMS issues paymentand claims processing information https://t.co/lCwn198PAN
30 Apr 2015 Social Negative RCT of RTX vs PBO in pts w/ ITP (PLT<30k) on background steroids. No difference in response or relapse rates http://buff.ly/1HHoCni 
17 Feb 2017 Social ORAL strategy trial shows Xeljanz +MTX = Humira +MTX; but was inferior as monoRx Xeljanz in 1152 RA pts over 12 mos https://t.co/hb6RdEnWj6
19 Aug 2017 Social RheumNow Wk in Review up! How to store enbrel, over/under testing. Check out podcast https://t.co/I5b8tFK7Oa video https://t.co/rJ2nMY6woD